EBEtienne Benoit

Etienne Benoit

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Etienne Benoit has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Christiane Longin-Sauvageon

    UMR 1233 INRA/ENVL Metabolisme des Xenobiotiques et Mycotoxines Universite Lyon 1, National Veterinary School of Lyon, Marcyl' Etoile

    2 shared publications
  • Philippe Berny

    VetAgro Sup Campus vétérinaire de Lyon, 1 avenue Bourgelat, F-69280 Marcy l’Étoile (France)

    2 shared publications
  • Romain Lasseur

    Liphatech (De Sangosse group), Research and Development Unit, Bonnel, Pont du Casse, France

    2 shared publications
  • Agnes Grandemange

    UMR INRA/ENVL Metabolisme des Xenobiotiques et Mycotoxines Universite Lyon, Bonnel, Pont du Casse, France

    1 shared publication
  • Agnès Grandemange

    UMR 1233 INRA/DGER, Métabolisme des Xénobiotiques et Mycotoxines, Lyon College of Veterinary Medicine, BP 83, 69280 Marcy l'Etoile, France

    1 shared publication
  • Christiane Longin‐Sauvageon

    UMR 1233 INRA/DGER, Métabolisme des Xénobiotiques et Mycotoxines, Lyon College of Veterinary Medicine, BP 83, 69280 Marcy l'Etoile, France

    1 shared publication

Latest Publications

  • Consequences of the Y139F Vkorc1 mutation on resistance to AVKs: in-vivo investigation in a 7th generation of congenic Y139F strain of rats

    by Agnes Grandemange, Michael Hans Kohn, Romain Lasseur, Christiane Longin-Sauvageon, Philippe Berny, Etienne Benoit

    Objectives In humans, warfarin is used as an anticoagulant to reduce the risk of thromboembolic clinical events. Warfarin derivatives are also used as rodenticides in pest control. The gene encoding the protein targeted by anticoagulants is the Vitamin K-2,3-epoxide reductase subunit 1 (VKORC1). Since its discovery in 2004, various amino acid and transcription-regulatory altering VKORC1 mutations have been identified in patients who required extreme antivitamin K dosages, or wild populations of rodents that were difficult to control with anticoagulant rodenticides. One unresolved question concerns the dependency of the VKORC1 on the genetic background in humans and rodents that respond weakly or not at all to anticoagulants. Moreover, an important question requiring further analyses concerns the role of the Vkorc1 gene in mediating resistance to more recently developed warfarin derivatives (superwarfarins). Methods In this study, we bred a quasicongenic rat strain by using a wild-caught anticoagulant resistant rat as a donor to introduce the Y>F amino acid change at position 139 in the Vkorc1 into the genetic background of an anticoagulant susceptible Spraque–Dawley recipient strain. Results and conclusion In this manuscript we report the prothrombin times measured in the F7 generation after exposure to chlorophacinone, bromadiolone, difenacoum and difethialone. We observed that the mutation Y139F mediates resistance in an otherwise susceptible genetic background when exposed to chlorophacinone and bromadiolone. However, the physiological response to the super-warfarins, difenacoum and difethialone, may be strongly dependent on other genes located outside the congenic interval (28.3 cM) bracketing the Vkorc1 in our F7 generation congenic strain.


  • Heterogeneity of the coumarin anticoagulant targeted vitamin K epoxide reduction system. Study of kinetic parameters in susceptible and resistant mice (Mus musculus domesticus)

    by Romain Lasseur, Agnès Grandemange, Christiane Longin‐Sauvageon, Philippe Berny, Etienne Benoit

    Vitamin K epoxide reductase (VKOR) activity in liver microsomes from a susceptible and a genetically warfarin-resistant strain of mice (Mus Musculus domesticus) was analyzed to determine the mechanism of resistance to this 4-hydroxycoumarin derivative. Kinetic parameters for VKOR were calculated for each strain by incubating liver microsomes with vitamin K epoxide ± warfarin. In susceptible mice, an Eadie–Hofstee plot of the data was not linear and suggested the involvement of at least two different components. Apparent kinetic parameters were obtained by nonlinear regression using a Michaelis--Menten model, which takes into account two enzymatic components. Component A presents a high Km and a high Vm, and as a consequence only an enzymatic efficiency Vm/Km was obtained (0.0024 mL/min/mg). Estimated warfarin Ki was 0.17 μM. Component B presented an apparent Km of 12.73 μM, an apparent Vm of 0.32 nmol/min/mg, and an apparent Ki for warfarin of 6.0 μM. In resistant mice, the enzymatic efficiency corresponding to component A was highly decreased (0.0003–0.00066 mL/min/mg) while the Ki for warfarin was not modified. The apparent Vm of component B was poorly modified between susceptible and resistant mice. The apparent Km of component B observed in resistant mice was similar to the Km observed in susceptible mice. These modifications of the catalytic properties are associated with a single nucleotide polymorphism (T175G) in the VKOR-C1 gene, which corresponds to a Trp59Gly mutation in the protein. © 2006 Wiley Periodicals, Inc. J Biochem Mol Toxicol 20:221–229, 2006; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/jbt.20144


  • Identification and characterization of the FMO2 gene in Rattus norvegicus

    by Marine Hugonnard, Etienne Benoit, Christiane Longin-Sauvageon, Virginie Lattard

    Background In lung of many animal species flavin-containing monooxygenase 2 (FMO2) is a 535-amino acid residues drug-metabolizing enzyme. In humans FMO2 exhibits a genetic polymorphism. The major allele encodes a truncated FMO2, the minor allele a full-length FMO2. In laboratory rats we previously reported a FMO2 gene encoding a truncated FMO2 (432-AA residues). In these strains, a double deletion leads to the appearance of a premature stop codon. All laboratory rat strains were derived from the same wild ancestor, Rattus norvegicus. Methods A PCR-based method able to specifically recognize either the wild-type or the mutant allele was developed to investigate a putative FMO2 polymorphism in a population of wild rats. The FMO2 gene was analyzed in 42 wild rats. Results A genetic FMO2 polymorphism similar to that described in humans was found in R. norvegicus. We observed three different genotypes: homozygotes for the wild-type FMO2 (33.3%), homozygotes for the mutant FMO2 (38.1%) and heterozygotes (28.6%). Comparative FMO2 mRNA and protein expressions in lungs were studied by reverse transcription–PCR and western blotting. FMO2 mRNA expression was identical between the three groups. In contrast, major differences in the expression of FMO2 protein were detected. FMO2 was strongly expressed in lungs of homozygotes for the wild-type FMO2, faintly expressed in lungs of heterozygotes and non-expressed in lungs of homozygotes for the mutant FMO2. Comparative catalytic properties of lung microsomes were studied by the determination of the oxygenation of methimazole. FMO2 genetic polymorphism was associated with major differences in the S-oxidative metabolism.